Analysis

RSS feed for this section
This category contains 76 posts

Will the FDA Remove Zevalin’s Bioscan?

By Trevor Sherwood ⋅ November 18, 2011 ⋅ 2 comments

In the next few days, the FDA is expected to announce whether or not Spectrum Pharmaceuticals’ (NASDAQ: SPPI) Zevalin should still require a pre-treatment screen, termed the “bioscan”, possibly removing what management believes is the last hurdle to a dramatic increase in Zevalin prescriptions. Zevalin is an antibody attached to Yttrium-90, a radioactive isotope that [...]

DUSA Pharmaceuticals Shares Tumble After Earnings Release: Low Growth Ahead?

By Steven Breazzano ⋅ November 11, 2011 ⋅ Post a comment

  DUSA Pharmaceuticals, Inc. (DUSA) – based in Wilmington, MA is a dermatology company engaged in the development and commercialization of Levulan photodynamic therapy (PDT).  Utilizing their proprietary Kerastick 20% Topical Solution with PDT and the BLU-U brand light source for the treatment of non-hyperkeratotic actinic keratoses (AKs) of the face or scalp, the company [...]

Inhibitex Announces Positive Topline Data in HCV Program

By Trevor Sherwood ⋅ November 8, 2011 ⋅ Post a comment

Last week, Inhibitex (NASDAQ: INHX) updated guidance on its program in HCV with positive top-line data from the first cohort of a trial of INX-189 in treatment-naïve patients infected with genotype 1 HCV. Patients in this arm received 200 mg of Inhibitex’s nucleotide polymerase inhibitor INX-189 once daily and saw a median reduction in viral [...]

LPath Investors Have iSONEP Trial Results in Sight

By Steven Breazzano ⋅ November 1, 2011 ⋅ Post a comment

Upcoming events: PEDigree phase Ib/2a preliminary data late Q1 2012 or early Q2 2012 LPath, Inc. (LPTN.OB) – based in San Diego, CA engages in the development and commercialization of lipidomic-based therapeutics.  Utilizing their proprietary ImmuneY2™ discovery engine, the company aims to leverage its technology platform to provide monoclonal antibodies targeting bioactive lipids in a [...]

«Previous —